Genetics Institute, a Cambridge, Mass, biotechnology company,...

Genetics Institute, a Cambridge, Mass, biotechnology company, was ordered by a federal judge not to export for 10 days an anti-anemia drug it is developing. This is the latest round in a series of patent infringement lawsuits that have been filed between Genetics Institute and Amgen, a Thousand Oaks biotechnology concern. Both companies have filed a request with the Food and Drug Administration that would allow them to sell their versions of the anti-anemia drug erythropoietin. The worldwide market for the drug has been estimated by analysts at $1 billion a year or more.